Abstract

Nonalcoholic steatohepatitis (NASH) is triggered by hepatocyte death through activation of caspase 6, as a result of decreased adenosine monophosphate (AMP)-activated protein kinase-alpha (AMPKα) activity. Increased hepatocellular death promotes inflammation which drives hepatic fibrosis. We show that the nuclear-localized mitogen-activated protein kinase (MAPK) phosphatase-1 (MKP1) is upregulated in NASH patients and in NASH diet fed male mice. The focus of this work is to investigate whether and how MKP1 is involved in the development of NASH. Under NASH conditions increased oxidative stress, induces MKP1 expression leading to nuclear p38 MAPK dephosphorylation and decreases liver kinase B1 (LKB1) phosphorylation at a site required to promote LKB1 nuclear exit. Hepatic deletion of MKP1 in NASH diet fed male mice releases nuclear LKB1 into the cytoplasm to activate AMPKα and prevents hepatocellular death, inflammation and NASH. Hence, nuclear-localized MKP1-p38 MAPK-LKB1 signaling is required to suppress AMPKα which triggers hepatocyte death and the development of NASH.

Nonalcoholic steatohepatitis (NASH) is a devastating type of liver disease that is caused by hepatocellular death which triggers liver inflammation and fibrosis. Here, the authors show that MAP kinase phosphatase-1 promotes hepatocellular death thus, driving the development of NASH.

Details

Title
MKP1 promotes nonalcoholic steatohepatitis by suppressing AMPK activity through LKB1 nuclear retention
Author
Qiu, Bin 1   VIAFID ORCID Logo  ; Lawan, Ahmed 2   VIAFID ORCID Logo  ; Xirouchaki, Chrysovalantou E. 3 ; Yi, Jae-Sung 1 ; Robert, Marie 4 ; Zhang, Lei 1 ; Brown, Wendy 5 ; Fernández-Hernando, Carlos 6   VIAFID ORCID Logo  ; Yang, Xiaoyong 7   VIAFID ORCID Logo  ; Tiganis, Tony 8   VIAFID ORCID Logo  ; Bennett, Anton M. 9   VIAFID ORCID Logo 

 Yale University School of Medicine, Department of Pharmacology, New Haven, USA (GRID:grid.47100.32) (ISNI:0000 0004 1936 8710); Yale University School of Medicine, Yale Center of Molecular and Systems Metabolism, New Haven, USA (GRID:grid.47100.32) (ISNI:0000 0004 1936 8710) 
 University of Alabama, Department of Biological Sciences, Huntsville, USA (GRID:grid.411015.0) (ISNI:0000 0001 0727 7545) 
 Monash University, Monash Biomedicine Discovery Institute, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); Monash University, Department of Biochemistry and Molecular Biology, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857) 
 Yale University School of Medicine, Department of Pathology, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710) 
 Alfred Hospital, Melbourne, Monash University Department of Surgery, Victoria, Australia (GRID:grid.1623.6) (ISNI:0000 0004 0432 511X) 
 Yale University School of Medicine, Yale Center of Molecular and Systems Metabolism, New Haven, USA (GRID:grid.47100.32) (ISNI:0000 0004 1936 8710); Yale University School of Medicine, Department of Pathology, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); Yale University School of Medicine, Vascular Biology and Therapeutics Program, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); Yale University School of Medicine, Department of Comparative Medicine, New Haven, USA (GRID:grid.47100.32) (ISNI:0000 0004 1936 8710) 
 Yale University School of Medicine, Yale Center of Molecular and Systems Metabolism, New Haven, USA (GRID:grid.47100.32) (ISNI:0000 0004 1936 8710); Yale University School of Medicine, Department of Comparative Medicine, New Haven, USA (GRID:grid.47100.32) (ISNI:0000 0004 1936 8710) 
 Monash University, Monash Biomedicine Discovery Institute, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); Monash University, Department of Biochemistry and Molecular Biology, Clayton, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857); Yale University School of Medicine, Department of Comparative Medicine, New Haven, USA (GRID:grid.47100.32) (ISNI:0000 0004 1936 8710) 
 Yale University School of Medicine, Department of Pharmacology, New Haven, USA (GRID:grid.47100.32) (ISNI:0000 0004 1936 8710); Yale University School of Medicine, Yale Center of Molecular and Systems Metabolism, New Haven, USA (GRID:grid.47100.32) (ISNI:0000 0004 1936 8710); Yale University School of Medicine, Vascular Biology and Therapeutics Program, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); Yale University School of Medicine, Department of Comparative Medicine, New Haven, USA (GRID:grid.47100.32) (ISNI:0000 0004 1936 8710) 
Pages
5405
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2861030886
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.